Literature DB >> 6203759

Neurochemical and behavioral effects of systemic and intranigral administration of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the rat.

C C Chiueh, S P Markey, R S Burns, J N Johannessen, A Pert, I J Kopin.   

Abstract

At doses of 5-10 mg kg-1, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (NMPTP) produces in rats acute immobility, retropulsion, straub tail, piloerection, exophthalmos, salivation and clonic movements of the forepaws. It does not produce analgesia as measured by the tail test, nor does it produce permanent motor impairment after chronic or intranigral administration. The acute retropulsion and immobilizing effects can be blocked by methysergide. Administered acutely, NMPTP doubles levels of serotonin in the raphe nucleus and substantia nigra. At the same time, levels of dopamine increase in the caudate nucleus and decrease in the substantia nigra. The NMPTP-induced decrease in dopamine content of the substantia nigra persists in chronically treated rats, but there is no significant decrease in striatal dopamine. After chronic administration of NMPTP, striatal levels of dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) were decreased by about 50%. Intranigral administrations of NMPTP (10 micrograms daily for 5 days) failed to produce a 6-hydroxydopamine-like lesion in the nigrostriatal system. These results indicate that NMPTP in the rat does not cause selective destruction of dopaminergic neurons, but it does produce acute tryptamine-like effects.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6203759     DOI: 10.1016/0014-2999(84)90221-8

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  21 in total

Review 1.  Intranasal administration of neurotoxicants in animals: support for the olfactory vector hypothesis of Parkinson's disease.

Authors:  Rui D S Prediger; Aderbal S Aguiar; Filipe C Matheus; Roger Walz; Layal Antoury; Rita Raisman-Vozari; Richard L Doty
Journal:  Neurotox Res       Date:  2011-10-15       Impact factor: 3.911

2.  Proceedings of the British Pharmacological Society. University of Dundee, 11th-14th September, 1984. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1984-12       Impact factor: 8.739

3.  Neurotoxic damage to the nigrostriatal system in rats following intranigral administration of MPDP+ and MPP+.

Authors:  C J Sun; J N Johannessen; W Gessner; I Namura; W Singhaniyom; A Brossi; C C Chiueh
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

4.  Parkin-knockout mice did not display increased vulnerability to intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

Authors:  Aderbal S Aguiar; Fabrine S M Tristão; Majid Amar; Caroline Chevarin; Laurence Lanfumey; Raymond Mongeau; Olga Corti; Rui D Prediger; Rita Raisman-Vozari
Journal:  Neurotox Res       Date:  2013-04-16       Impact factor: 3.911

5.  Single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice models early preclinical phase of Parkinson's disease.

Authors:  Rui D S Prediger; Aderbal S Aguiar; Argelia Esperanza Rojas-Mayorquin; Claudia P Figueiredo; Filipe C Matheus; Laure Ginestet; Caroline Chevarin; Elaine Del Bel; Raymond Mongeau; Michel Hamon; Laurence Lanfumey; Rita Raisman-Vozari
Journal:  Neurotox Res       Date:  2009-07-21       Impact factor: 3.911

6.  Paradoxical sleep deprivatory effect of a single low dose of MPTP which did not produce dopaminergic cell loss.

Authors:  K Pungor; A Hajnal; K A Kékesi; G Juhász
Journal:  Exp Brain Res       Date:  1993       Impact factor: 1.972

7.  1,2,3,4-Tetrahydro-2-methyl-4,6,7-isoquinolinetriol inhibits tyrosine hydroxylase activity in rat striatal synaptosomes.

Authors:  J Liptrot; D Holdup; O Phillipson
Journal:  J Neural Transm Gen Sect       Date:  1994

8.  Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity.

Authors:  J A Javitch; R J D'Amato; S M Strittmatter; S H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  1985-04       Impact factor: 11.205

9.  Prevention of dopaminergic toxicity of MPTP in mice by phenylethylamine, a specific substrate of type B monoamine oxidase.

Authors:  E Melamed; M B Youdim
Journal:  Br J Pharmacol       Date:  1985-11       Impact factor: 8.739

Review 10.  Parkinson's disease treatment: past, present, and future.

Authors:  John D Elsworth
Journal:  J Neural Transm (Vienna)       Date:  2020-03-14       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.